{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/CDX"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CDX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CDX\",,,,,undefined,":{"symbol":"CDX","market":"US","secType":"STK","nameCN":"SIMPLIFY HIGH YIELD PLUS CREDIT HEDGE ETF","latestPrice":23.09,"timestamp":1753473600000,"preClose":22.98,"halted":0,"volume":256452,"hourTrading":{"tag":"盘后","latestPrice":23.09,"preClose":23.09,"latestTime":"16:26 EDT","volume":1505,"amount":34750.59,"timestamp":1753475186732},"delay":0,"floatShares":12700001,"shares":0,"eps":0,"marketStatus":"Market Closed","change":0.11,"latestTime":"07-25 16:00:00 EDT","open":23.03,"high":23.09,"low":23,"amount":5911442.34088,"amplitude":0.003916,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1753689600000},"marketStatusCode":7,"adr":0,"exchange":"ARCA","adjPreClose":22.98,"sharesOutstanding":12700001,"nav":22.97,"aum":291707289.36,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":23.09,"preClose":23.09,"latestTime":"16:26 EDT","volume":1505,"amount":34750.59,"timestamp":1753475186732},"volumeRatio":0.6279650271413968},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CDX\",,,,,undefined,":{"symbol":"CDX","floatShares":12700001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.6279650271413968,"shares":0,"dividePrice":0,"high":23.09,"amplitude":0.003916,"preClose":22.98,"low":23,"week52Low":21.57,"pbRate":"--","week52High":24.89,"institutionHeld":0,"latestPrice":23.09,"eps":0,"divideRate":0,"volume":256452,"delay":0,"ttmEps":0,"open":23.03,"prevYearClose":21.81,"prevWeekClose":22.92,"prevMonthClose":23.32,"prevQuarterClose":23.32,"fiveDayClose":22.92,"twentyDayClose":23.25,"sixtyDayClose":23.03},"@#url:\"https://hq.skytigris.cn/market/plate/belongs/CDX\",params:#limit:6,delay:false,,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CDX\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2530168605","title":"Zymeworks Presents New Data from Multiple Development Programs at 2025 AACR Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2530168605","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530168605?lang=en_us&edition=fundamental","pubTime":"2025-04-26 01:00","pubTimestamp":1745600400,"startTime":"0","endTime":"0","summary":"Six posters highlight continued progress across antibody-drug conjugate and T cell engager platforms. Novel T cell engager ZW209 demonstrates durable activity in small cell lung cancer; IND submission expected in 1H-2026. “The breadth of data shared at AACR highlights the strength of our oncology portfolio across antibody-drug conjugates and T cell engagers, and demonstrates the novel approaches we employ using each modality,” said Paul Moore, Ph.D., Chief Scientific Officer at Zymeworks. “We’re particularly excited to share data on ZW209, the latest of our oncology nominated IND programs which has demonstrated promising anti-tumor activity in preclinical small cell lung cancer models by integrating CD28 co-stimulation into a trispecific T cell engager. We look forward to advancing ZW209 with an IND submission anticipated in the first half of 2026, while also progressing the differentiated programs in our wholly-owned pipeline.”","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/zymeworks-presents-data-multiple-development-170000085.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TIL","BK4218","BK4139","BTC","ZYME","BK4181","PDX","PK","BK4505","CDX"],"gpt_icon":0},{"id":"2518239084","title":"Market Sentiment Around Loss-Making CardieX Limited (ASX:CDX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2518239084","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518239084?lang=en_us&edition=fundamental","pubTime":"2025-03-10 06:19","pubTimestamp":1741558797,"startTime":"0","endTime":"0","summary":"CardieX Limited  is possibly approaching a major achievement in its business, so we would like to shine some light on the company. CardieX Limited engages in the design, manufacture, and marketing of medical devices used in cardiovascular health management in the Americas, Europe, and the Asia Pacific. The company’s loss has recently broadened since it announced a AU$6.8m loss in the full financial year, compared to the latest trailing-twelve-month loss of AU$15m, moving it further away from breakeven. The most pressing concern for investors is CardieX's path to profitability – when will it breakeven?Below we will provide a high-level summary of the industry analysts’ expectations for the company.According to some industry analysts covering CardieX, breakeven is near. They expect the company to post a final loss in 2025, before turning a profit of AU$24m in 2026. Therefore, the company is expected to breakeven just over a year from today. What rate will the company have to grow year-on","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/market-sentiment-around-loss-making-221957528.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["CDEX","CDX.AU","BK7007","CDX"],"gpt_icon":0},{"id":"2516635849","title":"Celldex Therapeutics Presents Positive Preclinical Data from Inflammatory Bispecific Antibody Program CDX-622 at AAAAI 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2516635849","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516635849?lang=en_us&edition=fundamental","pubTime":"2025-03-03 21:01","pubTimestamp":1741006860,"startTime":"0","endTime":"0","summary":"- CDX-622 inhibits SCF and TSLP-dependent inflammatory signatures in human skin -- Phase 1 study in healthy volunteers ongoing - HAMPTON, N.J., March  03, 2025  (GLOBE NEWSWIRE) -- Celldex Therapeutic","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/03/3035595/24180/en/Celldex-Therapeutics-Presents-Positive-Preclinical-Data-from-Inflammatory-Bispecific-Antibody-Program-CDX-622-at-AAAAI-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CDX","BK4139","TSLP","CLDX"],"gpt_icon":0},{"id":"2512496071","title":"When Will CardieX Limited (ASX:CDX) Turn A Profit?","url":"https://stock-news.laohu8.com/highlight/detail?id=2512496071","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512496071?lang=en_us&edition=fundamental","pubTime":"2025-02-19 07:01","pubTimestamp":1739919716,"startTime":"0","endTime":"0","summary":"CardieX Limited ( ASX:CDX ) is possibly approaching a major achievement in its business, so we would like to shine some...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice2-main-header/1585186837163","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice2-main-header/1585186837163"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/healthcare/asx-cdx/cardiex-shares/news/when-will-cardiex-limited-asxcdx-turn-a-profit","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7007","CDEX","CDX.AU","CDX"],"gpt_icon":0}],"pageSize":4,"totalPage":1,"pageCount":1,"totalSize":4,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CDX\",params:#limit:5,,,undefined,":[{"date":"2025-06-25","symbol":"CDX","amount":0.15,"announcedDate":"2025-06-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-25","defaultRemindTime":1750858200000,"name":"SIMPLIFY HIGH YIELD PLUS CREDIT HEDGE ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-30","payableDate":"2025-06-25","currency":"USD","dateTimestamp":1750824000000,"payDate":"2025-06-30"},{"date":"2025-05-27","symbol":"CDX","amount":0.15,"announcedDate":"2025-05-23","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-05-27","defaultRemindTime":1748352600000,"name":"SIMPLIFY HIGH YIELD PLUS CREDIT HEDGE ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-05-30","payableDate":"2025-05-27","currency":"USD","dateTimestamp":1748318400000,"payDate":"2025-05-30"},{"date":"2025-04-25","symbol":"CDX","amount":0.15,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-04-25","defaultRemindTime":1745587800000,"name":"SIMPLIFY HIGH YIELD PLUS CREDIT HEDGE ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-30","payableDate":"2025-04-25","currency":"USD","dateTimestamp":1745553600000,"payDate":"2025-04-30"},{"date":"2025-03-26","symbol":"CDX","amount":0.15,"announcedDate":"2025-03-25","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-26","defaultRemindTime":1742995800000,"name":"SIMPLIFY HIGH YIELD PLUS CREDIT HEDGE ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-31","payableDate":"2025-03-26","currency":"USD","dateTimestamp":1742961600000,"payDate":"2025-03-31"},{"date":"2025-02-25","symbol":"CDX","amount":0.05,"announcedDate":"2025-02-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-02-25","defaultRemindTime":1740493800000,"name":"SIMPLIFY HIGH YIELD PLUS CREDIT HEDGE ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-02-28","payableDate":"2025-02-25","currency":"USD","dateTimestamp":1740459600000,"payDate":"2025-02-28"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CDX\",market:\"US\",,,undefined,":[{"executeDate":"2022-03-28","recordDate":"2022-03-29","paymentDate":"2022-03-31","value":0.0631,"currency":"USD"},{"executeDate":"2022-04-26","recordDate":"2022-04-27","paymentDate":"2022-04-29","value":0.08882,"currency":"USD"},{"executeDate":"2022-05-25","recordDate":"2022-05-26","paymentDate":"2022-05-31","value":0.10303,"currency":"USD"},{"executeDate":"2022-06-27","recordDate":"2022-06-28","paymentDate":"2022-06-30","value":0.09614,"currency":"USD"},{"executeDate":"2022-07-26","recordDate":"2022-07-27","paymentDate":"2022-07-29","value":0.06047,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CDX\",market:\"US\",delay:false,,,undefined,":{}}}